Logo

Telix Reports the First Patient Dosing of TLX101 in P-II (IPAX-Linz) Study for the Treatment of Glioblastoma

Share this
Telix Reports the First Patient Dosing of TLX101 in P-II (IPAX-Linz) Study for the Treatment of Glioblastoma

Telix Reports the First Patient Dosing of TLX101 in P-II (IPAX-Linz) Study for the Treatment of Glioblastoma

Shots:

  • The first patient has been dosed in a P-II investigator-initiated (IPAX-Linz) study evaluating TLX101 + external beam radiation therapy (EBRT) in patients with recurrent HGG incl. GBM. The study was led by Professor Josef Pichler at Kepler University Hospital in Linz, Austria
  • The (IPAX-1) study results showed a favorable safety profile along with an encouraging preliminary therapeutic effect & continues to provide benefits to patients in 2L settings at neuro-oncology sites in the EU
  • TLX101 (4-L-[131I] iodo-phenylalanine) has received ODD from the US FDA & EMA that targets L-type amino acid transporter 1 (LAT-1) for the treatment of malignant tumours incl. HGG/GBM

Ref: PRNewswire | Image: Telix

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions